Updates in Urologic Oncology


ENDING THE RELIANCE ON BCG
A Phase III clinical trial for bladder cancer

The Phase III randomized trial compares Bacillus Calmette-Guerin (BCG) immunotherapy, the standard-of-care intravesical treatment for high grade non-muscle invasive bladder cancer, versus intravesical Docetaxel and Gemcitabine treatment in BCG naïve patients.

Fox Chase Cancer Center Welcomes Dr. J. Ryan Mark

Fox Chase Cancer Center is pleased to announce the hiring of J. Ryan Mark, MD, FACS, as an Associate Professor in the Department of Urology at Fox Chase Cancer Center and a Fox Chase – Temple Urologic Institute provider.

Optimizing Treatment Strategies for Localized and Advanced Genitourinary Malignancies

The Fox Chase genitourinary oncology team cover the latest advancements in surgical techniques, radiation therapies, and medical treatments for both localized and advanced bladder, kidney, and prostate cancers.

Tackling Anything Patients Need Before, During, and After Urologic Surgery

Growing up, Mary Ellen Day was athletic and focused—dreaming that one day, she would become a ‘real’ cheerleader.

Fox Chase Cancer Center and Lewis Katz School of Medicine Researchers Identify Where to Target Interventions to Reduce Disparities in Aggressive Prostate Cancer

Researchers at Fox Chase Cancer Center and Lewis Katz School of Medicine at Temple University have identified factors that, if addressed, could decrease incidence of aggressive prostate cancer in areas where rates are highest — often Black ...

Fox Chase Cancer Center Opens First New Jersey Location in Voorhees

Fox Chase Cancer Center is proud to welcome patients to its newly opened office, which is located at 502 Centennial Boulevard, Suite 7, in Voorhees, New Jersey.